PAP
DMRA

Persistent Asset Partners’s Damora Therapeutics DMRA Stock Holding History

Persistent Asset Partners’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
8,084
+2,746
+51% +$66.5K 0.06% 208
2026
Q1 		$138K Buy
+5,338
New +$137K 0.05% 220

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Persistent Asset Partners's DMRA Position: Q2 2026 in Review

Persistent Asset Partners increased its Damora Therapeutics (DMRA) stake by 51% in Q2 2026, buying an estimated $66.5K and bringing the position to 8,084 shares worth $210K. The position accounts for 0.06% of the portfolio, ranked #208.

Persistent Asset Partners first reported a position in DMRA in Q1 2026 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Persistent Asset Partners held 8,084 shares of Damora Therapeutics worth $210K as of Q2 2026.
  • Persistent Asset Partners bought 2,746 Damora Therapeutics shares in Q2 2026, an estimated $66.5K.
  • Damora Therapeutics made up 0.06% of Persistent Asset Partners's portfolio in Q2 2026, its #208 holding.
  • Persistent Asset Partners first reported a position in Damora Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.